NCT03701880

Early Use of Ivabradine in Heart Failure

The Impact of Ivabradine Administration on Clinical Outcome and Biomarkers of Decompensated Heart Failure

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the work is to Evaluate the efficacy, quality of life and safety of early addition of ivabradine to B-blocker in reduced EF heart failure patients after acute decompensation compared to the standard treatment.

Detailed description

this study is a Prospective randomized open label study will be conducted on Egyptian patient with heart failure with reduced ejection fraction(rEF HF). Each of the eligible patients will be randomized to one of these groups, early administration of Ivabradine and B-blocker group or control group which follows American Heart Association treatment guidelines of rEF HF. The objectives include the following: 1. Physical examination (heart rate, blood pressure, dyspnea and orthopnea symptoms) 2. NYHA class 3. Pro-NT-BNP serum level, ST2 serum level 4. Echocardiography (left ventricular ejection fraction) 5. Score of Minnesota Living with Heart Failure Questionnaire these objectives will be measured baseline, 2 weeks and after 3 months

Conditions

• Heart Failure With Reduced Ejection Fraction
• Decompensated Heart Failure

Interventions

Type	Name	Description
DRUG	Ivabradine	Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
DRUG	Bisoprolol	Bisoprolol is beta-blocker

Timeline

• Start date: 2018-09-16
• Primary completion: 2019-12-23
• Completion: 2019-12-23
• First posted: 2018-10-10
• Last updated: 2018-10-11

Locations

1 site across 1 country: Egypt